| Literature DB >> 34187463 |
Songtao Lu1, Dongmei Wei1, Chao Yin2, Juwen Xiong3, Lishuang Zhu4, Shaoru Yan5, Rui Meng6.
Abstract
BACKGROUND: This study aims to explore the correlation between procalcitonin (PCT), 25-hydroxyvitamin D3 (25(OH)D), pentraxin-3 (PTX-3), amylase (AMS) levels and severity of diabetic ketoacidosis complicated by pancreatitis.Entities:
Keywords: 25-hydroxyvitamin D3; Amylase; Diabetic ketoacidosis; Pancreatitis; Pentraxin-3; Procalcitonin; Severity of illness
Mesh:
Substances:
Year: 2021 PMID: 34187463 PMCID: PMC8244139 DOI: 10.1186/s12902-021-00792-9
Source DB: PubMed Journal: BMC Endocr Disord ISSN: 1472-6823 Impact factor: 2.763
Population characteristics
| Characteristics | DKA-AP | DKA | Control | χ2/Z | |
|---|---|---|---|---|---|
| Sex, n (%) | |||||
| Female | 21 (56.76) | 91 (56.52) | 38 (52.78) | 0.307 | 0.856 |
| Male | 16 (43.24) | 70 (43.48) | 34 (47.22) | ||
| Age, year | 63.29 ± 6.72 | 62.98 ± 7.01 | 64.01 ± 6.92 | 0.346 | 0.708 |
| BMI, kg/m2 | 24.38 ± 3.01 | 24.19 ± 2.78 | 24.09 ± 2.68 | 0.267 | 0.766 |
| Biochemical parameters | |||||
| Creatine, μmol/L | 118.76 ± 18.73 | 117.98 ± 13.29 | 56.98 ± 6.93 | 391.612 | < 0.001 |
| HbAlc, % | 9.01 ± 2.02 | 8.91 ± 1.97 | 5.37 ± 0.76 | 110.988 | < 0.001 |
| BUN, mmol/L | 5.74 ± 0.34 | 5.43 ± 0.31 | 5.01 ± 0.28 | 130.692 | < 0.001 |
| LDL, mmol/L | 3.02 ± 0.76 | 2.99 ± 0.26 | 2.87 ± 0.27 | 1.431 | 0.241 |
| HDL, mmol/L | 1.05 ± 0.21 | 0.92 ± 0.18 | 0.68 ± 0.23 | 76.904 | < 0.001 |
| AST, U/L | 56.83 ± 8.92 | 29.98 ± 2.19 | 28.08 ± 2.01 | 458.502 | < 0.001 |
| ALT, U/L | 63.19 ± 7.62 | 27.99 ± 2.23 | 27.23 ± 1.87 | 996.273 | < 0.001 |
| CO2CP, mmol/L | 30.08 ± 2.72 | 29.76 ± 1.08 | 28.08 ± 1.03 | 9.296 | < 0.001 |
| Blood glucose, mol/L | 13.02 ± 2.18 | 10.76 ± 1.92 | 5.36 ± 1.29 | 390.662 | < 0.001 |
| Blood potassium, mmol/L | 4.38 ± 0.28 | 4.26 ± 0.23 | 4.01 ± 0.19 | 53.713 | < 0.001 |
| Blood sodium, mmol/L | 147.93 ± 32.09 | 144.99 ± 31.29 | 142.97 ± 29.84 | 0.659 | 0.518 |
| Bloog ketone, M (P25, P75), mmol/L | 4.83 (3.47, 6.03) | 0.06 (0, 0.20) | 0.03 (0, 0.18) | 69.876 | < 0.001 |
| hs-TnT, M (P25, P75), μg/L | 0.08 (0.03, 0.019) | 0.02 (0.02, 0.03) | 0.01 (0, 0.14) | 31.876 | < 0.001 |
| BNP, ng/L | 85.43 ± 6.38 | 67.98 ± 8.27 | 54.39 ± 5.83 | 616.474 | < 0.001 |
| TG, mmol/L | 2.73 ± 0.63 | 2.69 ± 0.59 | 2.51 ± 0.48 | 3.562 | 0.03 |
| TC, mmol/L | 5.17 ± 0.47 | 4.82 ± 0.39 | 4.51 ± 0.23 | 66.639 | < 0.001 |
| Lactate, M (P25, P75), mmol/L | 2.71 (1.06, 4.73) | 0.91 (0.51, 1.69) | 0.89 (0.50, 1.61) | 56.543 | < 0.001 |
| pH | 7.4 ± 0.26 | 7.1 ± 0.23 | 7.0 ± 0.09 | 84.499 | < 0.001 |
| Frequency of diabetic ketoacidosis, M (P25, P75) | 2 (1, 3) | 0 (0, 1) | 0 | 10.987 | < 0.001 |
| Onset age of diabetes, M (P25, P75), year | 35 (26, 58) | 36 (28, 59) | 0 | −0.519 | 0.606 |
| Type of diabetes, n (%) | |||||
| Type I | 17 | 85 | 0 | 12.923 | < 0.001 |
| Type II | 19 | 41 | 0 | ||
| Unkown | 1 | 35 | 0 | ||
| Duration of diabetes, M (P25, P75), year | 9 (0.6, 19) | 0 (0, 1) | 0 | 8.876 | < 0.001 |
| Complications, n (%) | |||||
| Vascular complications | 17 (45.95) | 31 (19.25) | 0 | 11.671 | 0.001 |
| Abdominal pain | 33 (81.08) | 22 (13.66) | 0 | 85.542 | < 0.001 |
| Delirium | 2 (5.41) | 14 (8.70) | 0 | 0.438 | 0.508 |
ALT Alanine aminotransferase, AST Aspartate aminotransferase, BMI Body mass index, BNP Brain natriuretic peptide, BUN Blood urea nitrogen, COCP Carbondioxide combining power, HbA Hemoglobin A1C, HDL High density lipoprotein, hs-cTnT High sensitivity cardiac troponin testing, LDL Low density lipoprotein, TC Total cholesterol, TG Triacylglyceride
The levels of PCT, 25(OH)D, PTX-3 and AMS among groups
| Group | PCT, mg/L | 25(OH)D, ng/mL | PTX-3, ng/mL | AMS, mmol/L |
|---|---|---|---|---|
| DKA-AP ( | 1.32 ± 0.32#* | 3.17 ± 0.34#* | 10.52 ± 0.64#* | 398.76 ± 26.65#* |
DKA ( | 0.87 ± 0.15* | 15.87 ± 0.86* | 0.34 ± 0.06* | 107.65 ± 12.87* |
| Control ( | 0.21 ± 0.08 | 30.65 ± 1.32 | 0.29 ± 0.04 | 45.87 ± 8.76 |
| Z | 609.246 | 366.05 | 707.278 | 571.808 |
| < 0.001 | < 0.001 | < 0.001 | < 0.001 |
AMS Amylase, PCT Procalcitonin, PTX-3 Pentraxin-3, 25(OH)D 25-hydroxyvitamin D3. #, compared with the level on day 1 after admission, P < 0.05; *, compared with DKA group, P < 0.05
Fig. 1Levels of PCT in DKA-AP and DKA groups. #, compared with the level on day 1 after admission, P < 0.05; *, compared with DKA group, P < 0.05. PCT, procalcitonin
Fig. 2Levels of 25(OH)D in DKA-AP and DKA groups. #, compared with the level on day 1 after admission, P < 0.05; *, compared with DKA group, P < 0.05. 25(OH)D, 25-hydroxyvitamin D3
Fig. 3Levels of PTX-3 in DKA-AP and DKA groups. #, compared with the level on day 1 after admission, P < 0.05; *, compared with DKA group, P < 0.05. PTX-3, PTX-3, pentraxin-3
Fig. 4Levels of AMS in DKA-AP and DKA groups. #, compared with the level on day 1 after admission, P < 0.05; *, compared with DKA group, P < 0.05. AMS, amylase
The clinical outcomes between DKA-AP and DKA groups
| Group | Duration of hospital stay, M (P25, P75), d | Patients of ICU care, n | Duration of ICU stay, M (P25, P75), d | Mortality, n (%) | Cost, M (P25, P75), ten thousand yuan |
|---|---|---|---|---|---|
| DKA-AP ( | 13 (9, 16) | 20 (54.05) | 4 (3, 5) | 2 (5.41) | 2.91 (1.98, 3.92) |
| DKA ( | 10 (7, 16) | 55 (34.16) | 1 (0, 3) | 3 (1.86) | 1.87 (1.21, 2.92) |
| χ2/Z | 24.516 | 5.063 | 12.691 | 1.592 | 5.762 |
| < 0.001 | 0.024 | < 0.001 | 0.229 | 0.016 |
ICU Intensive care unit